Moderate to Severe Atopic Dermatitis Study

Controlled Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis

woman scratching her hand

 

AGE: 18-55 years old
SEX AT BIRTH: All
TYPE: Investigational Treatment Study
CONDITION: Atopic Dermatitis (Eczema)
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center

Learn More About This Research Study

For more information, please contact study coordinator, Dr. Emma Larson at at 216-844-5278 or by completing the form below.

Study Purpose

The purpose of this study is to evaluate the impact of lebrikizumab on vaccine responses (TDaP and meningococcal) in patients with moderate-to-severe Atopic Dermatitis. This study will further assess the efficacy and safety of lebrikizumab in patients with AD.

Who Can Participate

Participants between 18-55 years old with moderate to severe atopic dermatitis (eczema) and have not had a TDaP or meningococcal vaccines in the last 5 years may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

XXX-XXX-XXXX

STUDY ID#

  • STUDY20201892